- Home
- MYGN vs GRAL Comparison
MYGN vs GRAL Comparison
Compare MYGN & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- GRAL
- Stock Information
- Founded
- MYGN 1991
- GRAL 2016
- Country
- MYGN United States
- GRAL United States
- Employees
- MYGN N/A
- GRAL N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GRAL
- Sector
- MYGN Health Care
- GRAL
- Exchange
- MYGN Nasdaq
- GRAL NYSE
- Market Cap
- MYGN 744.7M
- GRAL 877.1M
- IPO Year
- MYGN 1995
- GRAL N/A
- Fundamental
- Price
- MYGN $4.13
- GRAL $39.91
- Analyst Decision
- MYGN Hold
- GRAL Buy
- Analyst Count
- MYGN 16
- GRAL 3
- Target Price
- MYGN $16.40
- GRAL $31.50
- AVG Volume (30 Days)
- MYGN 3.4M
- GRAL 1.6M
- Earning Date
- MYGN 05-06-2025
- GRAL 05-13-2025
- Dividend Yield
- MYGN N/A
- GRAL N/A
- EPS Growth
- MYGN N/A
- GRAL N/A
- EPS
- MYGN N/A
- GRAL N/A
- Revenue
- MYGN $831,300,000.00
- GRAL $130,711,000.00
- Revenue This Year
- MYGN N/A
- GRAL $23.72
- Revenue Next Year
- MYGN $7.21
- GRAL $15.47
- P/E Ratio
- MYGN N/A
- GRAL N/A
- Revenue Growth
- MYGN 7.38
- GRAL 30.47
- 52 Week Low
- MYGN $3.98
- GRAL $12.33
- 52 Week High
- MYGN $29.30
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- MYGN 25.47
- GRAL N/A
- Support Level
- MYGN $3.81
- GRAL N/A
- Resistance Level
- MYGN $4.31
- GRAL N/A
- Average True Range (ATR)
- MYGN 0.47
- GRAL 0.00
- MACD
- MYGN -0.16
- GRAL 0.00
- Stochastic Oscillator
- MYGN 8.00
- GRAL 0.00
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.